Developer docs
API playgroundTry for free, no card

Search company profiles

Cresset

Full company profile

uuid0007wvp

Namestring
Cresset
Legal namestring
Cresset Biomolecular Discovery Limited
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Cresset is a UK-based computational chemistry company developing software and contract research services for small molecule drug discovery and design. Founded in 2002 by Andy Vinter on the basis of his proprietary XED force field research, the company operates as Cresset Biomolecular Discovery Limited from Litlington, UK, and employs between 101 and 250 people. Its customer base spans pharmaceutical and biotechnology companies, agrochemical firms, flavors and fragrance developers, and academic research institutions.

The core offering is the Flare platform, a ligand and structure-based drug design environment that bundles Free Energy Perturbation (FEP) calculations, virtual screening (Blaze), scaffold hopping and bioisosteric replacement (Spark), AI-powered ADME prediction, and collaborative design (Flare Connect). The XED force field, which models molecular electrostatics using extended electron distributions rather than standard atom-centered charges, underpins the platform and supports more accurate prediction of aromatic stacking, hydrogen bonding, and protein-ligand interactions. In June 2026, Cresset released Flare V12, more than doubling FEP calculation speed via the SOMD2 engine and adding support for ring-breaking transformations, replica exchange sampling, and Grand Canonical Monte Carlo water sampling.

Revenue derives from software licensing (subscription, project-based rental, and evaluation pathways) and from Cresset Discovery Services, a contract research arm delivering project-based or flexible-day engagements to clients that include Jazz Pharmaceuticals, Evotec, LifeArc, BASF, MOA Technology, and Epics Therapeutics. Growth capital from Scottish Equity Partners in September 2022 funded product development and US expansion. Subsequent strategic actions include a July 2025 acquisition of Molab, a March 2026 brand identity refresh positioning the company around AI-enriched simulation and partnership, and integration of AstraZeneca's REINVENT4 generative AI technology (branded MolGenAI) within Flare.

Short descriptiontext

Cresset provides computational chemistry software (Flare, Spark, Blaze) and contract drug discovery services for small molecule design, serving pharmaceutical, biotechnology, agrochemical, and academic customers globally through direct enterprise sales and CRO engagements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational chemistry software, drug discovery software, molecular modeling services, virtual screening platform, medicinal chemistry CRO
Industry1 code
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Computational Drug Discovery Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Software Licensing
TypeSubscription Recurring
Description

Cresset licenses its drug discovery software (Flare, Spark, Blaze) to pharmaceutical and biotech companies. Software is available via direct licensing and project-based rental models, allowing organizations flexible access to computational chemistry tools.

cresset-group.com
2Discovery Services (CRO)
TypeProfessional Services
Description

Cresset Discovery Services provides contract research services applying computational chemistry expertise to client drug discovery projects. Services include virtual screening, hit discovery, lead optimization, QSAR analysis, and molecular modeling. Available via task-based or flexible service days engagement models.

cresset-group.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Cresset develops and licenses AI-enriched computational chemistry software for small molecule drug discovery, anchored by its Flare platform and add-on modules for Free Energy Perturbation, scaffold hopping, virtual screening, ADME prediction and collaborative design. The company also operates a contract research organisation (Cresset Discovery Services) that applies its proprietary XED force field and simulation methods to client hit discovery, hit-to-lead and lead optimisation projects.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >80% compute time savings in FEP calculations with Active Learning workflow
+3 more records
Product overview1 text field

Cresset offers a portfolio of computational drug discovery software products centered on its Flare™ platform, complemented by specialized modules and Discovery Services. The core Flare platform provides comprehensive ligand and structure-based drug design capabilities, which are extended by dedicated modules for Free Energy Perturbation (Flare FEP), AI-powered ADME prediction (AI ADME), scaffold hopping (Spark), virtual screening (Blaze), and collaborative design (Flare Connect). The company also operates as a contract research organization offering Discovery Services that leverage proprietary XED force field technology and AI-enriched simulation methods. The product portfolio is designed to accelerate discovery from target validation through candidate selection, serving computational chemists, medicinal chemists, and academic researchers.

Product and service7 records
1Flare
2Spark
3Blaze
4Flare FEP
CategoryComputational Drug Discovery Software
Description

Free Energy Perturbation module for predicting binding affinity and relative binding free energies of compounds, using advanced simulation methods including SOMD2, replica exchange and Grand Canonical Monte Carlo water sampling.

5AI ADME
6Flare Connect
7Cresset Discovery Services
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on METTL3 inhibitor drug discovery project. Cresset Discovery delivered digital workflow combining molecular modeling expertise with Cresset technology to accelerate hit discovery and optimization. Project resulted in published research and progression toward in-vivo proof of concept compound.

Strategic tierNotableTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Ashraf Zarkan from Department of Genetics on UTI drug discovery project. Combined computational methods with in-silico drug discovery expertise to identify novel inhibitors targeting E. coli enzyme for treating urinary tract infections.

Strategic tierNotableTypeStrategic or Co-development Partner
Description

Collaboration on drug repurposing research identifying anti-cancer activities of existing drugs. Cresset Discovery team employed Blaze virtual screening and Flare molecular modeling to discover anti-viral drug Rilpivirine showed anti-proliferative actions in cancer cell lines.

4MolGenAI (AstraZeneca)
Strategic tierStrategicTypeTechnology or Integration
Description

Integration of AstraZeneca's REINVENT4 generative AI technology (MolGenAI) within Flare software platform. Provides AI-powered generative chemistry capabilities for novel molecule design and exploration of new chemical space.

cresset-group.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public computational chemistry and molecular simulation software company serving pharma and biotech with FEP+, LiveDesign, and a discovery services arm. Direct competitor to Flare and Cresset Discovery across ligand/structure-based design, FEP, and CRO services.

TypeBroad incumbent
Description

Broad life sciences software suite within Dassault Systèmes covering discovery, clinical, and manufacturing. Overlaps with Cresset on molecular modeling and drug discovery but serves as part of an enterprise-wide portfolio rather than a chemistry specialist.

TypeDirect peer
Description

Pioneer in ligand-based virtual screening and shape/electrostatic similarity methods (ROCS, OMEGA), now part of Cadence. Direct competitor to Blaze and Flare in cheminformatics and small molecule design.

TypeDirect peer
Description

Long-established provider of the Molecular Operating Environment (MOE) platform for drug discovery, including docking, pharmacophore modeling, and QSAR. Direct competitor in integrated ligand/structure-based design software.

TypeDirect peer
Description

Scientific R&D platform spanning data, analytics, and chemistry for drug discovery workflows. Comparable in serving medicinal and computational chemists across pharma/biotech with software tools that overlap Cresset's user base.

TypeDirect peer
Description

Specialist in pharmacophore modeling (LigandScout), property prediction, and metabolite prediction software for drug discovery. Niche direct competitor in cheminformatics tools used by computational and medicinal chemists.

TypeBroad incumbent
Description

Public drug development services and software company covering discovery through regulatory submission. Adjacent to Cresset's discovery services arm with broader downstream reach into PBPK modeling and regulatory science.

TypeEmerging player
Description

Smaller cheminformatics and computational chemistry software vendor offering field-based similarity and pharmacophore tools. Niche competitor to Blaze/Spark with narrower feature breadth.

TypeEmerging player
Description

AI-first drug discovery company with generative chemistry, target discovery, and an integrated pipeline. Competes for the same AI-physics discovery budget and represents both a partner archetype and disruptive adjacent entrant.

TypeRegional player
Description

Large CRO with integrated drug discovery platforms, including computational chemistry and in silico services. A current Cresset customer/partner and an indirect competitor on the discovery services side, though with much broader wet-lab capabilities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cresset

Computational Drug Discovery Softwarecresset-group.com

Cresset provides computational chemistry software (Flare, Spark, Blaze) and contract drug discovery services for small molecule design, serving pharmaceutical, biotechnology, agrochemical, and academic customers globally through direct enterprise sales and CRO engagements.

What Cresset does

Cresset is a UK-based computational chemistry company developing software and contract research services for small molecule drug discovery and design. Founded in 2002 by Andy Vinter on the basis of his proprietary XED force field research, the company operates as Cresset Biomolecular Discovery Limited from Litlington, UK, and employs between 101 and 250 people. Its customer base spans pharmaceutical and biotechnology companies, agrochemical firms, flavors and fragrance developers, and academic research institutions.

The core offering is the Flare platform, a ligand and structure-based drug design environment that bundles Free Energy Perturbation (FEP) calculations, virtual screening (Blaze), scaffold hopping and bioisosteric replacement (Spark), AI-powered ADME prediction, and collaborative design (Flare Connect). The XED force field, which models molecular electrostatics using extended electron distributions rather than standard atom-centered charges, underpins the platform and supports more accurate prediction of aromatic stacking, hydrogen bonding, and protein-ligand interactions. In June 2026, Cresset released Flare V12, more than doubling FEP calculation speed via the SOMD2 engine and adding support for ring-breaking transformations, replica exchange sampling, and Grand Canonical Monte Carlo water sampling.

Revenue derives from software licensing (subscription, project-based rental, and evaluation pathways) and from Cresset Discovery Services, a contract research arm delivering project-based or flexible-day engagements to clients that include Jazz Pharmaceuticals, Evotec, LifeArc, BASF, MOA Technology, and Epics Therapeutics. Growth capital from Scottish Equity Partners in September 2022 funded product development and US expansion. Subsequent strategic actions include a July 2025 acquisition of Molab, a March 2026 brand identity refresh positioning the company around AI-enriched simulation and partnership, and integration of AstraZeneca's REINVENT4 generative AI technology (branded MolGenAI) within Flare.

Cresset firmographics

Firmographics
Name
Cresset
Legal name
Cresset Biomolecular Discovery Limited
Website
https://cresset-group.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
51–100 employees
Short description
Cresset provides computational chemistry software (Flare, Spark, Blaze) and contract drug discovery services for small molecule design, serving pharmaceutical, biotechnology, agrochemical, and academic customers globally through direct enterprise sales and CRO engagements.
Ownership category
akta.pro rank

Cresset industry classification

Industry
Product category
Computational Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)

Keywords

  • Computational chemistry software
  • Drug discovery software
  • Molecular modeling services
  • Virtual screening platform
  • Medicinal chemistry CRO

Where Cresset is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Cresset business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Software Licensing: Cresset licenses its drug discovery software (Flare, Spark, Blaze) to pharmaceutical and biotech companies. Software is available via direct licensing and project-based rental models, allowing organizations flexible access to computational chemistry tools.
  2. Discovery Services (CRO): Cresset Discovery Services provides contract research services applying computational chemistry expertise to client drug discovery projects. Services include virtual screening, hit discovery, lead optimization, QSAR analysis, and molecular modeling. Available via task-based or flexible service days engagement models.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Cresset product offering

Product offering

Core offering

Cresset develops and licenses AI-enriched computational chemistry software for small molecule drug discovery, anchored by its Flare platform and add-on modules for Free Energy Perturbation, scaffold hopping, virtual screening, ADME prediction and collaborative design. The company also operates a contract research organisation (Cresset Discovery Services) that applies its proprietary XED force field and simulation methods to client hit discovery, hit-to-lead and lead optimisation projects.

Product overview

Cresset offers a portfolio of computational drug discovery software products centered on its Flare™ platform, complemented by specialized modules and Discovery Services. The core Flare platform provides comprehensive ligand and structure-based drug design capabilities, which are extended by dedicated modules for Free Energy Perturbation (Flare FEP), AI-powered ADME prediction (AI ADME), scaffold hopping (Spark), virtual screening (Blaze), and collaborative design (Flare Connect). The company also operates as a contract research organization offering Discovery Services that leverage proprietary XED force field technology and AI-enriched simulation methods. The product portfolio is designed to accelerate discovery from target validation through candidate selection, serving computational chemists, medicinal chemists, and academic researchers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Flare
  • Spark
  • Blaze
  • Flare FEP Free Energy Perturbation module for predicting binding affinity and relative binding free energies of compounds, using advanced simulation methods including SOMD2, replica exchange and Grand Canonical Monte Carlo water sampling.
  • AI ADME
  • Flare Connect
  • Cresset Discovery Services

Quantifiable outcome

  • >80% compute time savings in FEP calculations with Active Learning workflow
  • +3 more outcomes

Companies that use Cresset

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Cresset technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Cresset partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, notable and strategic.

  • Epics TherapeuticscoreStrategic or Co-development PartnerCollaboration on METTL3 inhibitor drug discovery project. Cresset Discovery delivered digital workflow combining molecular modeling expertise with Cresset technology to accelerate hit discovery and optimization. Project resulted in published research and progression toward in-vivo proof of concept compound.
  • University of CambridgenotableStrategic or Co-development PartnerCollaboration with Dr. Ashraf Zarkan from Department of Genetics on UTI drug discovery project. Combined computational methods with in-silico drug discovery expertise to identify novel inhibitors targeting E. coli enzyme for treating urinary tract infections.
  • University of South AustralianotableStrategic or Co-development PartnerCollaboration on drug repurposing research identifying anti-cancer activities of existing drugs. Cresset Discovery team employed Blaze virtual screening and Flare molecular modeling to discover anti-viral drug Rilpivirine showed anti-proliferative actions in cancer cell lines.
  • MolGenAI (AstraZeneca)strategicTechnology or IntegrationIntegration of AstraZeneca's REINVENT4 generative AI technology (MolGenAI) within Flare software platform. Provides AI-powered generative chemistry capabilities for novel molecule design and exploration of new chemical space.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Cresset competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Public computational chemistry and molecular simulation software company serving pharma and biotech with FEP+, LiveDesign, and a discovery services arm. Direct competitor to Flare and Cresset Discovery across ligand/structure-based design, FEP, and CRO services.
  • OpenEye Scientific Software (Cadence Design Systems): Pioneer in ligand-based virtual screening and shape/electrostatic similarity methods (ROCS, OMEGA), now part of Cadence. Direct competitor to Blaze and Flare in cheminformatics and small molecule design.
  • Chemical Computing Group (MOE): Long-established provider of the Molecular Operating Environment (MOE) platform for drug discovery, including docking, pharmacophore modeling, and QSAR. Direct competitor in integrated ligand/structure-based design software.
  • Dotmatics: Scientific R&D platform spanning data, analytics, and chemistry for drug discovery workflows. Comparable in serving medicinal and computational chemists across pharma/biotech with software tools that overlap Cresset's user base.
  • Molecular Discovery Ltd: Specialist in pharmacophore modeling (LigandScout), property prediction, and metabolite prediction software for drug discovery. Niche direct competitor in cheminformatics tools used by computational and medicinal chemists.

Broad incumbents

  • Dassault Systèmes BIOVIA: Broad life sciences software suite within Dassault Systèmes covering discovery, clinical, and manufacturing. Overlaps with Cresset on molecular modeling and drug discovery but serves as part of an enterprise-wide portfolio rather than a chemistry specialist.
  • Certara: Public drug development services and software company covering discovery through regulatory submission. Adjacent to Cresset's discovery services arm with broader downstream reach into PBPK modeling and regulatory science.

Emerging players

  • Pharmacelera: Smaller cheminformatics and computational chemistry software vendor offering field-based similarity and pharmacophore tools. Niche competitor to Blaze/Spark with narrower feature breadth.
  • Insilico Medicine: AI-first drug discovery company with generative chemistry, target discovery, and an integrated pipeline. Competes for the same AI-physics discovery budget and represents both a partner archetype and disruptive adjacent entrant.

Regional players

  • Evotec: Large CRO with integrated drug discovery platforms, including computational chemistry and in silico services. A current Cresset customer/partner and an indirect competitor on the discovery services side, though with much broader wet-lab capabilities.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cresset social profiles

Digital presence

Cresset financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cresset leadership team

Management profile

Number of profiles

Profiles6 records

Cresset funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cresset M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cresset

What does Cresset do?

Cresset develops and licenses AI-enriched computational chemistry software for small molecule drug discovery, anchored by its Flare platform and add-on modules for Free Energy Perturbation, scaffold hopping, virtual screening, ADME prediction and collaborative design. The company also operates a contract research organisation (Cresset Discovery Services) that applies its proprietary XED force field and simulation methods to client hit discovery, hit-to-lead and lead optimisation projects.

Is Cresset a public or private company?

Cresset is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cresset founded?

Cresset was founded in 2002. It employs 51 to 100 people.

Where is Cresset based?

Cresset is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Cresset make money?

Two revenue lines are on record. Software Licensing is the primary driver. The others are discovery Services (CRO).

Who are Cresset's main competitors?

Direct peers on record are Schrödinger, OpenEye Scientific Software (Cadence Design Systems), Chemical Computing Group (MOE), Dotmatics and Molecular Discovery Ltd. Broad incumbents are Dassault Systèmes BIOVIA and Certara. Emerging players are Pharmacelera and Insilico Medicine. Evotec is listed as a regional player.

Does Cresset have an API?

No public API is recorded for Cresset.

What industry is Cresset in?

Cresset's product category is Computational Drug Discovery Software. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireCresset releases Flare V12 to cut synthesis and testing cycles with faster, more flexible FEPCresset released Flare V12, a computer-aided drug design update that cuts Free Energy Perturbation calculation times by over 50% while maintaining accuracy. The version adds support for complex transformations like ring-breaking and covalent ligands, aiming to make FEP more usable in routine discovery workflows.Cresset-GroupCresset Acquires Molab.ai to Advance Digitization of Drug DiscoveryCresset acquired Molab.ai, an AI company for molecular research, to combine its computational chemistry platform with Molab.ai's predictive ADME models. The acquisition aims to unify prediction tools for drug discovery, with Molab.ai continuing operations and integrating into Cresset's AI team.NatureMerck: Innovation powered by digital and dataThis sponsored feature article describes Merck's digital and data innovation strategy across its healthcare, life science, and electronics sectors, detailing platforms including AIDDISON for AI-powered drug discovery, BayBE for AI-assisted experimental planning, SYNTHIA retrosynthesis software, Syntropy for healthcare data collaboration, and Athinia for semiconductor industry data sharing. The article highlights how Merck leverages AI, machine learning, and data ecosystems to accelerate drug discovery and optimize manufacturing across its business units, referencing strategic partnerships with companies like BioSolveIT, Cresset, and Palantir. Merck reports that BayBE powers approximately 30 internal use cases and notes market research projecting AI could generate over US$70 billion in drug discovery savings by 2028, though no fully AI-generated drug has yet been approved.Drug Discovery World (DDW)AI: Advancing drug discovery with ultra-large library processingRob Scoffin and Matthew Habgood of Cresset discuss how integrating artificial intelligence and machine learning into virtual screening methods accelerates drug discovery by processing ultra-large compound libraries. This approach allows for the in silico screening of billions of virtual compounds, significantly reducing reliance on costly 'wet lab' experiments and improving the identification of potential drug candidates. The article highlights recent successes, such as FDA orphan drug designations for AI-designed compounds, indicating the growing maturity of this technology.PharmiWeb.comCresset® Announces Global Collaboration with Enamine on New Virtual Screening Drug Discovery TechnologyCresset and Enamine announced a collaboration to develop virtual screening technology for ultra-large chemical spaces. The Ignite technology, applied to Enamine's REAL Space library of over 38 billion make-on-demand molecules, enables 3D screening with efficiency gains of more than a hundredfold. A webinar on the topic is scheduled for March 5.Barron'sPaul Tramontano: Why Our Advisor Team Moved From First Republic to CressetAfter Constellation Wealth Advisors moved from First Republic Bank to Cresset Capital in April, most of its clients followed, according to co-head Paul Tramontano. Tramontano said the loyalty was earned over decades, noting clients are convinced the firm puts their interests first.Cresset-GroupCresset secures significant growth funding from SEPCresset, a UK-based drug discovery software scaleup, has secured growth capital from Scottish Equity Partners (SEP) to further its product development and expand internationally. The funding is intended to enhance Cresset's software offerings, which aid in drug discovery workflows, and accelerate its growth in the US market. This collaboration reflects a strategic partnership aimed at innovating drug development processes.GlobeNewswireBioFocus collaborates with Cresset to develop new range of compound librariesBioFocus and Cresset are collaborating to develop a new range of targeted compound libraries for high-value drug targets such as GPCRs and ion channels. The partnership uses Cresset's FieldTemplater molecular field modelling technology to identify novel chemical classes. The libraries aim to accelerate drug discovery programs for customers.